drugset / Trial / NCT00960336

Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer

NCT00960336 ↗

Phase 2 Completed 59 enrolled ARCAGY/ GINECO GROUP
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well doxorubicin hydrochloride liposome works as first-line therapy in treating older women with metastatic breast cancer.

Timeline

Start
2008-03
Primary completion
2011-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 40 mg/m2 Intravenous

Indications